



Contacts: Susan Lehman
Rockpoint Public Relations
+1 (510) 832-6006
susan@rockpointpr.com

Stephanie Tomei
Public Relations Manager
+1 (408) 789-4234
stomei@accuray.com

St. Louis University Hospital Purchases Second CyberKnife® System

Major Academic Center Expands Cancer Treatment Access to Local Community

SUNNYVALE, Calif, March 3, 2008– Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that St. Louis University Hospital has purchased a second CyberKnife® Robotic Radiosurgery System for its western satellite location in Lake St. Louis, Mo. This satellite facility will allow those living in the rural communities easier access to the CyberKnife System's unique capabilities.

Saint Louis University Hospital acquired its first CyberKnife System in 2004 and has been using it to treat tumors in the brain, lung, pancreas and liver. A Certificate of Need (CON) meeting in Jefferson City, Mo., approved the hospital's purchase of a second CyberKnife System. Along with 36 other states, Missouri law requires hospitals to secure a Certificate of Need (CON) by demonstrating there is an unmet need for particular capital equipment or expansion before permission can be granted.

"St. Louis University Hospital is the most recent in a long line of centers that have elected to purchase a second CyberKnife System," said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "This further validates that demand for radiosurgery is exceeding the capacity of one CyberKnife System, supporting the purchase of multiple Systems."

Saint Louis University Hospital was the first facility in Missouri to begin using the CyberKnife System. Since then Mercy St. John's Hospital in Springfield, Mo., has also acquired a CyberKnife System.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which

minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, clinical studies, regulatory review and approval, and market acceptance and commercialization of products and services are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2007 fiscal year, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

###